GlassScriptPhysician profile
John A Whitfield
NPI 1104867324
$140,804.37
in general payments reported to CMS, 2019-2025
38 companies · $7,047 in 2025
The $7,047 reported for 2025 was more than what 94% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $28K · 2021: $32K · 2022: $1,131 · 2023: $8,486 · 2024: $15K · 2025: $7,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $1,894 · Travel and Lodging: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,067.50 |
| Food and Beverage | $1,894.10 |
| Travel and Lodging | $424.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $109,227.57 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $29,761.47 | 2022-2025 | Veozah |
| Lupin INC. | $211.55 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $196.23 | 2023-2025 | |
| Millicent US INC | $186.78 | 2019-2024 | Intrarosa |
| Vertical Pharmaceuticals, LLC | $124.53 | 2019-2020 | |
| Therapeuticsmd, INC. | $105.21 | 2019-2022 | |
| Aspira Women'S Health INC | $99.64 | 2020-2023 | Ova1 |
| Sumitomo Pharma America, INC. | $97.22 | 2025 | Myfembree |
| Exeltis, USA INC. | $87.87 | 2019-2025 | Slynd, Solosec |
| Daiichi Sankyo INC. | $73.31 | 2020 | |
| Agile Therapeutics, INC. | $71.27 | 2021-2023 | Twirla |
| Duchesnay USA Incorporated | $69.34 | 2019 | |
| Myovant Sciences INC. | $68.12 | 2022 | |
| Avion Pharmaceuticals | $62.94 | 2019-2023 | Balcoltra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $55.56 | 2022-2024 | Endosee |
| Bayer Healthcare Pharmaceuticals INC. | $42.32 | 2019 | |
| Organon LLC | $28.19 | 2022-2023 | Nexplanon |
| Allergan, INC. | $26.52 | 2019-2020 | |
| Caldera Medical, INC | $23.97 | 2025 | |
| Pfizer INC. | $22.24 | 2022 | |
| Scynexis, INC. | $22.17 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $21.32 | 2025 | |
| Meditrina | $20.65 | 2025 | |
| Mycovia Pharmaceuticals, INC. | $19.28 | 2022 | |
| Hologic Sales and Service, LLC | $19.02 | 2021 | |
| Ascend Therapeutics US, LLC | $17.43 | 2024 | |
| Shield Therapeutics INC | $15.34 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $15.32 | 2019 | |
| Minerva Surgical, INC | $11.99 | 2022 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Whitfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.